Darba, Josep and Ascanio, Meritxell and Rodriguez, Antonio and Charman, Sarah J. and Okwose, Nduka C. and Stefanetti, Renae J. and Groenewegen, Amy and Del Franco, Annamaria and Tafelmeier, Maria and Preveden, Andrej and Fuller, Amy S. and Bano, Fatima and Sinclair, David R. and Edwards, Duncan and Nelissen, Anne P. and Malitas, Petros N. and Zisaki, Aikaterini and Bosnic, Zoran and Vracar, Petar and Fornaro, Alessandra and Barlocco, Fausto and Fotiadis, Dimitris and Banerjee, Prithwish and MacGowan, Guy A. and Fernandez, Oscar and Zamorano, Jose Luis and Jimenez-blanco Bravo, Marta and Maier, Lars S. and Olivotto, Iacopo and Milli, Massimo and Rutten, Frans H. and Mant, Jonathan and Velicki, Lazar and Seferovic, Petar M. and Filipovic, Nenad and Jakovljevic, Djordje G. (2025) Economic burden of heart failure in Europe: A systematic review of costs and cost-effectiveness. ESC HEART FAILURE, 12 (6). pp. 4055-4068. ISSN 2055-5822,
Full text not available from this repository. (Request a copy)Abstract
Heart failure (HF) affects over 64 million individuals worldwide and is a major cause of hospitalization and mortality, particularly among older adults. In Europe, HF imposes a significant and growing economic burden. This systematic review aimed to evaluate the economic impact of HF diagnosis, treatment and management across European healthcare systems. A systematic literature search was conducted using PubMed, Cochrane Library and Econlit databases including the terms 'heart failure' AND 'costs' OR 'cost of illness' OR 'cost analysis' OR 'economic burden' OR 'cost effectiveness' OR 'primary care' OR 'secondary care'. Studies published between January 2000 and January 2024 were included. A total of 49 studies were included: 17 on resource use, 11 on costs, 15 on resource use and costs, 1 on costs and cost-effectiveness, and 5 on resource use, costs and cost-effectiveness. Hospitalizations and medication use were the most frequently reported resource parameters. Annual HF-related costs varied widely across countries, ranging from <euro>613 to <euro>22,647 per patient. Hospitalizations represented the primary cost driver, accounting for 15% to 92% of total HF costs. Cost-reduction strategies included multidisciplinary care, telemonitoring and pharmacologic interventions. Several disease management programmes reduced hospital admissions and emergency visits. Cost-effectiveness analyses supported the use of certain HF therapies, with incremental cost-effectiveness ratios ranging from <euro>1490 to <euro>9406 per QALY gained. F imposes a substantial economic burden in Europe, largely driven by hospitalizations. Cost-effective interventions such as remote monitoring and integrated care programmes can reduce this burden. Broader adoption of these strategies may improve outcomes and optimize resource allocation across healthcare systems.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | DISEASE MANAGEMENT PROGRAMS; HEALTH-CARE COSTS; MULTIDISCIPLINARY CARE; TRIAL; HOSPITALIZATION; PROGNOSIS; IMPACT; heart failure; healthcare costs; cost effectiveness; economic burden; resource utilization |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin II |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 18 Nov 2026 06:18 |
| Last Modified: | 18 Nov 2026 06:18 |
| URI: | https://pred.uni-regensburg.de/id/eprint/67980 |
Actions (login required)
![]() |
View Item |

